JLPC(SH:600513) Shang Hai Zheng Quan Bao·2025-05-26 19:22Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. plans to increase the registered capital of its wholly-owned subsidiary, Yangzhou Lianhuan Investment Co., Ltd., by 60 million RMB to enhance its core competitiveness and optimize its overall industrial layout [2][3]. Group 1: Capital Increase Overview - The capital increase will raise Yangzhou Lianhuan Investment's registered capital from 65 million RMB to 125 million RMB [3]. - The funding for this capital increase will come from the company's self-raised funds [2]. - The subsidiary currently has four holdings and investments across key sectors including pharmaceutical distribution, research and development, overseas investment, and new energy [3]. Group 2: Board Approval and Compliance - The board of directors approved the capital increase at the ninth temporary meeting held on May 26, 2025, and it does not require shareholder approval [4]. - The capital increase does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [5]. Group 3: Impact of Capital Increase - The capital increase will significantly enhance the financial strength of Yangzhou Lianhuan Investment, providing solid funding support for its investment projects [7]. - This move is expected to strengthen the company's risk resistance capabilities and optimize its revenue structure, aligning with the overall strategic planning of the company [7].